Company H. Lundbeck A/S

HLUN B

DK0061804770

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 16:20:00 11/03/2026 GMT			5-day change	1st Jan Change
37.52 ^DKK	-2.24%		-2.60%	-13.07%

03-10	H. Lundbeck A/S Appoints Markus Kede as Senior Vice President and Chief AI Officer and Joins Executive Leadership Team, Effective July 1, 2026	CI
03-10	H. Lundbeck Names Chief Artificial Intelligence Officer	MT

Business description: H. Lundbeck A/S

H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimerâ€™s disease, Bipolar disorder, depression, epilepsy, Huntingtonâ€™s disease, Parkinsonâ€™s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimerâ€™s disease, Azilect for the treatment of Parkinsonâ€™s disease, Xenazine for the treatment of Huntingtonâ€™s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.

Number of employees: 5,039

Sales by Activity: H. Lundbeck A/S

Fiscal Period: December	2021 (DKK)	2022 (DKK)	2023 (DKK)	2024 (DKK)	2025 (DKK)
Research, Development, Production and Sale of Pharmaceuticals	16.3B	18.25B	19.91B	22B	24.63B

See all business segments

Geographical breakdown of sales: H. Lundbeck A/S

Fiscal Period: December	2021 (DKK)	2022 (DKK)	2023 (DKK)	2024 (DKK)	2025 (DKK)
United States	7.46B	9.1B	9.83B	11.32B	13.29B
Europe	-	4.25B	4.63B	5.15B	5.82B
International Operations	4.16B	5.2B	4.99B	5.22B	4.86B
Unallocated	400M	-311M	464M	314M	666M
North America (Excl. US)	789M	-	-	-	-
Europe (Excl.Denmark)	3.47B	-	-	-	-
Denmark	30M	-	-	-	-

See all geographic segments

Executive Committee: H. Lundbeck A/S

Manager	Title	Age	Since
Charl van Zyl CEO	Chief Executive Officer	59	30/09/2023
Jörg Hornstein DFI	Director of Finance/CFO	49	31/08/2022
Michala Fischer-Hansen COO	Chief Operating Officer	52	-
Johan Luthman CTO	Chief Tech/Sci/R&D Officer	67	28/02/2019
Thomas Edward Gibbs PRN	Corporate Officer/Principal	55	27/02/2023

See H. LUNDBECK A/S governance

Composition of the Board of Directors: H. Lundbeck A/S

Director	Title	Age	Since
Lene Skole-Sørensen BRD	Director/Board Member	66	24/03/2015
Lars Erik Holmqvist BRD	Director/Board Member	66	24/03/2015
Jeffrey Berkowitz BRD	Director/Board Member	60	19/03/2018
Dorothea Wenzel CHM	Chairman	57	25/03/2025
Santiago Arroyo BRD	Director/Board Member	66	22/03/2021
Camilla Andersson BRD	Director/Board Member	54	31/12/2021
Hossein Armandi BRD	Director/Board Member	64	31/12/2021
Dorte Clausen BRD	Director/Board Member	42	31/12/2021
Lasse Skibsbye BRD	Director/Board Member	43	31/12/2021
Jakob Riis BRD	Director/Board Member	59	31/12/2022

Composition of the Board of Directors

Shareholders: H. Lundbeck A/S

Name	Equities	%	Valuation
Lundbeckfonden 66 %	525,751,306	66 %	3 219 M kr
Skagen AS 0.5321 %	4,239,000	0.5321 %	26 M kr
Sector Gamma AS 0.2552 %	2,033,195	0.2552 %	12 M kr
BNP Paribas Asset Management Belgium SA 0.2413 %	1,921,907	0.2413 %	12 M kr
Canaccord Genuity Wealth Ltd. 0.1594 %	1,269,997	0.1594 %	8 M kr

Name	Equities	%	Valuation
Lundbeckfonden 80 %	159,318,578	80 %	876 M kr
Nykredit Bank A/S (Investment Management) 0.5339 %	1,063,203	0.5339 %	6 M kr
Sparinvest SA (Denmark) 0.1056 %	210,209	0.1056 %	1 M kr
Equinor Asset Management ASA 0.0527 %	105,000	0.0527 %	577 434 kr
Niche Asset Management Ltd. 0.0461 %	91,744	0.0461 %	504 534 kr

List of H. LUNDBECK A/S shareholders

Company details: H. Lundbeck A/S

H. Lundbeck A/S

Ottiliavej 9

2500, Valby

+45 36 30 13 11

http://www.lundbeck.com

Pharmaceuticals Wholesale

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
H. LUNDBECK A/S	-2.24%	-2.60%	-3.55%	+25.23%	5.82B
MCKESSON CORPORATION	+0.60%	-4.54%	+43.03%	+177.90%	114B
CARDINAL HEALTH, INC.	-0.75%	-3.48%	+73.49%	+202.60%	51.07B
SIGMA HEALTHCARE LIMITED	-2.39%	-5.00%	-3.62%	-	22.59B
HUADONG MEDICINE CO., LTD	-0.14%	+4.89%	+1.78%	-23.44%	9.01B
SINOPHARM GROUP CO. LTD.	-0.67%	+0.58%	+5.91%	-4.15%	8.35B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+0.17%	+1.18%	-9.71%	-13.78%	8.31B
GALENICA AG	-1.22%	-0.64%	+13.14%	+33.12%	6.07B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD	-0.19%	+3.30%	+5.35%	-1.07%	3.87B
160 HEALTH INTERNATIONAL LIMITED	+28.49%	+58.65%	-	-	3.79B
Average	+2.18%	+2.34%	+13.98%	+49.55%	23.26B
Weighted average by Cap.	+0.26%	-3.45%	+37.72%	+148.20%